SlideShare una empresa de Scribd logo
1 de 26
Engaging Patients Through
Evidence-Based Medicine
  Margaret Holmes-Rovner, PhD
  MSU College of Human Medicine
  CMIO Conference, Chicago, Oct 3-4
What works? What doesn’t?

 Engagement in decision making
  – Encouraging decision making just before the
    encounter: question asking and coaching?
  – Patient access to electronic medical records?
  – Shared decision making with decision aids?
  – Patient centered interviewing?
 Engagement in chronic disease self-
  management
  Kinnersley BMJ 2008; Delbanco Ann Intern Med 2012; Stacy
    Cochrane 2011; Dwamena Cochrane forthcoming
What is Shared Decision
Making?

 Ensuring patient involvement in decisions
   – Provide evidence about the condition, options, long
     term and short term outcomes (Decision Aids help)
   – Clarify patients‟ values for the outcomes that matter
     to them (Engage with evidence)
   – Guide patients so the clinical choice matches their
     informed values.
   – Meaningful dialog rather than uni-directional
     disclosure (provider led, patient engaged)
O’Connor et al, Health Affairs, 2007
Road to Berwick’s triple aim

  Enhance the patient‟s experience (satisfaction
   increases)
  Improve the health of the population through
   patient engagement (adherence with
   negotiated plans)
  Decrease costs generated by over-use of tests
   and procedures

    Stacy D, Cochrane, 2011
    Arterburn DE, Health Affairs, 2012
Roots in Decision Analysis
                                         OpDeath
                                                     UDead
                                          pOpDeath
                               SURGERY                 NoSurv3
                                                                    UDead
                                                         pNoSurv3
                                         Survive                      SymL1
                                                                                 USymL1
                                               #                        pSymL1
                                                       Surv3          SymL2
                                                                                 USymL2
 CABG Medical or Surgical Rx                                   #        pSymL2
                                                                      SymL3
                                                                                 USymL3
                                                                             #
                                         MNoSurv3
                                                     UDead
                                         pMNoSurv3
                               MEDICAL                 MS ymL1
                                                                    USymL1
                                                        pMSymL1
                                         MS urv3       MS ymL2
                                                                    USymL2
                                               #        pMSymL2
                                                       MS ymL3
                                                                    USymL3
                                                               #
Preference-sensitive decisions?

   No one right answer for everyone
   Requires time for real informing/deciding
   Examples: -Lumpectomy vs mastectomy for early
    stage breast CA; -Active surveillance vs surgery vs
    radiation for early stage prostate cancer CA; -Stable
    CAD (today‟s example)
   “Sensitive” here means responsive to patients‟
    goals for outcomes AND concerns about side
    effects.
Applied health literacy in DAs
Choosing Wisely?

 Toss-ups: marginal added benefit to more
  aggressive therapies
 Therapeutic Misconception is widespread
  – Patients frequently think surgery means they can
    skip medical therapy, chronic disease self-
    management
 Patients may choose options providers are not
  happy about, to date, most often no treatment
   Smith, BMJ, 2010
PCI Example
PCI + Meds vs Meds alone in stable CAD
 No diff in risk of death or MI
 Function/quality of life improved in first 2 yrs. where chest
  pain not controlled by meds
 PCI should be an adjunct to meds in stable CAD
 Decreasing PCIs when not appropriate would:
   – Improve the quality of care for many patients
   – substantial healthcare savings

Boden, COURAGE trial, NEJM, 2007; Trikalinos, Lancet, 2009.
PCI Rates by Medicare Hosp.
Referral Regions, 2005
BCBSM PCI Utilization, 2008,
by HRR
Where in the diagnostic
therapeutic cascade?
 Cardiology pre-cath?
  – Most pressing, proximal to decision
  – Data suggest patients don‟t change their
    expectation of preventing heart attacks.
  – Even “enhanced informed consent” via video in a
    recent unpublished study doesn‟t change
    expectations or utilization
 Stress test?
 Primary care counseling in stable CAD
  patients for “anticipatory SDM”
                                                      14
Intervention is Not just a DA

   Initiated in primary care when a stress test is ordered
   Cardiology changed their results report to:
    1. Normal
    2. Abnormal with no high risk features
    3. Abnormal with high risk features
   # 1,2 go back to primary care for decision
   “After visit summary sheet” in primary care
   Care manager may do chronic disease self-
    management in cardiology or in primary care
Good Decision Aids exist?

 Science is strong
  – IPDAS update of background
  – Quality ratings of DAs: www.IPDAS.ohri.ca
 Public domain is growing (though limited)
 Private companies produce sets of DAs
 Recent Mass legislation will strengthen the
  public domain
What’s missing? Leadership

 Make it easy: DAs in the hands of providers
  and patients
 Make it delegatable by providers? (No)
  – Providers need brief training
 Improve care coordination? (Yes)
  – Primary care – Specialist
  – Providers - Care managers

 Holmes-Rovner, PEC, 2010
References

 Arterburn D, et al. Introducing decision aids at Group Health
  linked to sharply lower hip and knee surgery rates and costs.
  Health Aff. 2012;31:9,2094-2104.
 Boden, et al, COURAGE trial, NEJM. 2007; 2007 Apr
  12;356(15):1503
 Delbanco et al, Inviting patients to read their doctors‟ notes, Ann
  Intern Med, 157: 461-470.
 Holmes-Rovner M, et al, Shared Decision Making Guidance
  Reminders In Practice Pat Ed & Coun, 2011 Nov;85(2):219-24.
 Kinnersley P, Interventions before consultations to help patients
  address their information needs by encouraging question asking.
  BMJ. 2008 Jul 16;337:a485.
 O'Connor AM, et al. Toward the „tipping point‟: decision aids and
  informed patient choice, Health Affairs, 2007 May-Jun;26(3):716-
  25.
 Smith SK, et al, A decision aid to support informed choices about
  bowel cancer screening among adults with low education:
  randomised controlled trial. BMJ, 2010;341.
 Stacey D, et al, Dec Aids for people faciing health treatment or
  screening decisions. Cochrane Database System Reviews 2011,
  Issue 10.
 Trikalinos, PCI for non-acute CAD: quantitat 20-year synopsis
  and network meta-analysis. Lancet 2009. 2010;341.
How to do it? :
 Initiate conversation around shared decision-making
   – Set the stage for the visit
   – Set an agenda for the visit
   – Get the patient‟s story
 Relate to the patient by
   – Eliciting emotions
   – Expressing empathy
 Educate the patient about his/her unique situation with
  disease-specific information (Expanded in SDM.)
 Help patient to commit to engaging in the care of his/her
  stable CAD
 Negotiate an action plan (long-term and short-term) with
  the patient (SDM: 2-way discussion of options, patient
  goals, how best to accomplish them)

 Referral and documentation
More examples
PROSTATE CANCER
SCREENING

Más contenido relacionado

Destacado

Using the Library: Space, Resources, and Collaboration
Using the Library: Space, Resources, and CollaborationUsing the Library: Space, Resources, and Collaboration
Using the Library: Space, Resources, and CollaborationMsGrover1013
 
Reactie Vogelbescherming op Vogelbalans 2016
Reactie Vogelbescherming op Vogelbalans 2016Reactie Vogelbescherming op Vogelbalans 2016
Reactie Vogelbescherming op Vogelbalans 2016Sovon Vogelonderzoek
 
Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?
Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?
Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?Sovon Vogelonderzoek
 
Pim1221 7 menangkap ikan dengan trawl
Pim1221 7 menangkap ikan dengan trawlPim1221 7 menangkap ikan dengan trawl
Pim1221 7 menangkap ikan dengan trawlPT. SASA
 
Pim1221 3 klasifikasi alat tangkap
Pim1221 3 klasifikasi alat tangkapPim1221 3 klasifikasi alat tangkap
Pim1221 3 klasifikasi alat tangkapPT. SASA
 

Destacado (6)

Using the Library: Space, Resources, and Collaboration
Using the Library: Space, Resources, and CollaborationUsing the Library: Space, Resources, and Collaboration
Using the Library: Space, Resources, and Collaboration
 
Reactie Vogelbescherming op Vogelbalans 2016
Reactie Vogelbescherming op Vogelbalans 2016Reactie Vogelbescherming op Vogelbalans 2016
Reactie Vogelbescherming op Vogelbalans 2016
 
Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?
Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?
Blauwe Kiekendieven op de Meinweg: waar vandaan en waar naartoe?
 
Pim1221 7 menangkap ikan dengan trawl
Pim1221 7 menangkap ikan dengan trawlPim1221 7 menangkap ikan dengan trawl
Pim1221 7 menangkap ikan dengan trawl
 
Pim1221 3 klasifikasi alat tangkap
Pim1221 3 klasifikasi alat tangkapPim1221 3 klasifikasi alat tangkap
Pim1221 3 klasifikasi alat tangkap
 
Jaar van de Kievit
Jaar van de Kievit Jaar van de Kievit
Jaar van de Kievit
 

Similar a Engaging patients through evidence based medicine

OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...Tobias Meißner
 
Towards efficient therapies for small cell long cancer dr. n. haraszkiewicz...
Towards efficient therapies for small cell long cancer   dr. n. haraszkiewicz...Towards efficient therapies for small cell long cancer   dr. n. haraszkiewicz...
Towards efficient therapies for small cell long cancer dr. n. haraszkiewicz...Dr. Natalia Haraszkiewicz-Birkemeier
 
2014.12.pdf
2014.12.pdf2014.12.pdf
2014.12.pdfwil son
 
Immunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast CancerImmunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast Cancerbkling
 
Eldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_Interface
Eldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_InterfaceEldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_Interface
Eldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_InterfaceSimon Thomson
 
Nuevos tratº cáncer renal 2014
Nuevos tratº cáncer renal 2014Nuevos tratº cáncer renal 2014
Nuevos tratº cáncer renal 2014Martín Lázaro
 
Primary brain tumors in adults
Primary brain tumors in adultsPrimary brain tumors in adults
Primary brain tumors in adultsMaria Barreto
 
End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...
End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...
End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...Kevin Lee
 
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Howard Friedman
 
Estado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásicoEstado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásicoMauricio Lema
 
Risk stratification of scd
Risk stratification of scdRisk stratification of scd
Risk stratification of scdSunil Reddy D
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
 
YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12YMBioSciences
 
Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12YMBioSciences
 
Higher event rate in patients with known CAD despite a normal myocardial perf...
Higher event rate in patients with known CAD despite a normal myocardial perf...Higher event rate in patients with known CAD despite a normal myocardial perf...
Higher event rate in patients with known CAD despite a normal myocardial perf...Cardiovascular Diagnosis and Therapy (CDT)
 
Midwest Stroke Alliance VTE Presentation
Midwest Stroke Alliance VTE PresentationMidwest Stroke Alliance VTE Presentation
Midwest Stroke Alliance VTE PresentationMikePPAHS
 
Refractory dyslipedimia
Refractory dyslipedimiaRefractory dyslipedimia
Refractory dyslipedimia Mohamed BADR
 

Similar a Engaging patients through evidence based medicine (20)

The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Ea...
The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Ea...The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Ea...
The Evolving Role of Immunotherapy as a Component of Multimodal Therapy in Ea...
 
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
OncoRep: A n-of-1 reporting tool to support genome-guided treatment for breas...
 
Towards efficient therapies for small cell long cancer dr. n. haraszkiewicz...
Towards efficient therapies for small cell long cancer   dr. n. haraszkiewicz...Towards efficient therapies for small cell long cancer   dr. n. haraszkiewicz...
Towards efficient therapies for small cell long cancer dr. n. haraszkiewicz...
 
2014.12.pdf
2014.12.pdf2014.12.pdf
2014.12.pdf
 
Immunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast CancerImmunotherapy for Metastatic Triple Negative Breast Cancer
Immunotherapy for Metastatic Triple Negative Breast Cancer
 
Eldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_Interface
Eldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_InterfaceEldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_Interface
Eldabe_et_al-2015-Neuromodulation-_Technology_at_the_Neural_Interface
 
Treatement in progressive MS
Treatement in progressive MSTreatement in progressive MS
Treatement in progressive MS
 
Nuevos tratº cáncer renal 2014
Nuevos tratº cáncer renal 2014Nuevos tratº cáncer renal 2014
Nuevos tratº cáncer renal 2014
 
Primary brain tumors in adults
Primary brain tumors in adultsPrimary brain tumors in adults
Primary brain tumors in adults
 
End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...
End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...
End to end standards driven oncology study (solid tumor, Immunotherapy, Leuke...
 
2012, Veeravagu, et al, IM SC Mets, Contemp NS
2012, Veeravagu, et al, IM SC Mets, Contemp NS2012, Veeravagu, et al, IM SC Mets, Contemp NS
2012, Veeravagu, et al, IM SC Mets, Contemp NS
 
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
Real-World Treatment Patterns in Relapsed/Refractory Multiple Myeloma Patient...
 
Estado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásicoEstado actual de terapia sistémica en cáncer renal metastásico
Estado actual de terapia sistémica en cáncer renal metastásico
 
Risk stratification of scd
Risk stratification of scdRisk stratification of scd
Risk stratification of scd
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
 
YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12YM BioSciences CorpPres ASH2012 Dec 10 12
YM BioSciences CorpPres ASH2012 Dec 10 12
 
Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12Ym bio sciences corppres ash2012 dec 10 12
Ym bio sciences corppres ash2012 dec 10 12
 
Higher event rate in patients with known CAD despite a normal myocardial perf...
Higher event rate in patients with known CAD despite a normal myocardial perf...Higher event rate in patients with known CAD despite a normal myocardial perf...
Higher event rate in patients with known CAD despite a normal myocardial perf...
 
Midwest Stroke Alliance VTE Presentation
Midwest Stroke Alliance VTE PresentationMidwest Stroke Alliance VTE Presentation
Midwest Stroke Alliance VTE Presentation
 
Refractory dyslipedimia
Refractory dyslipedimiaRefractory dyslipedimia
Refractory dyslipedimia
 

Más de Trimed Media Group

Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)Trimed Media Group
 
Innovative technologies at ACC.15
Innovative technologies at ACC.15Innovative technologies at ACC.15
Innovative technologies at ACC.15Trimed Media Group
 
Imaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session SpotlightImaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session SpotlightTrimed Media Group
 
10 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.1510 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.15Trimed Media Group
 
6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuit6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuitTrimed Media Group
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalTrimed Media Group
 
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...Trimed Media Group
 
Kuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationKuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationTrimed Media Group
 
Safran info sage & disruptive innovation
Safran  info sage & disruptive innovationSafran  info sage & disruptive innovation
Safran info sage & disruptive innovationTrimed Media Group
 
[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis final[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis finalTrimed Media Group
 
Hamann big institution to community care
Hamann big institution to community careHamann big institution to community care
Hamann big institution to community careTrimed Media Group
 
Hongsermeier app store for health
Hongsermeier  app store for healthHongsermeier  app store for health
Hongsermeier app store for healthTrimed Media Group
 
Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...Trimed Media Group
 
Crotty engaging patients in new ways from open notes to social media
Crotty  engaging patients in new ways from open notes to social mediaCrotty  engaging patients in new ways from open notes to social media
Crotty engaging patients in new ways from open notes to social mediaTrimed Media Group
 

Más de Trimed Media Group (20)

HRS.15 Sessions to Attend
HRS.15 Sessions to AttendHRS.15 Sessions to Attend
HRS.15 Sessions to Attend
 
Himss cvb sessions
Himss cvb sessionsHimss cvb sessions
Himss cvb sessions
 
Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)Top 5 Sessions to attend at HIMSS.15 (CVB)
Top 5 Sessions to attend at HIMSS.15 (CVB)
 
Innovative technologies at ACC.15
Innovative technologies at ACC.15Innovative technologies at ACC.15
Innovative technologies at ACC.15
 
Imaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session SpotlightImaging at ACC.15: Session Spotlight
Imaging at ACC.15: Session Spotlight
 
10 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.1510 Sessions You Can’t Miss at ACC.15
10 Sessions You Can’t Miss at ACC.15
 
6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuit6 simple tips to help you avoid a lawsuit
6 simple tips to help you avoid a lawsuit
 
RSNA 2014
RSNA 2014RSNA 2014
RSNA 2014
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
 
Acep 10-15-13
Acep 10-15-13Acep 10-15-13
Acep 10-15-13
 
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...Shorr and bria  innovation at the point-of-care rethinking the doctor-patient...
Shorr and bria innovation at the point-of-care rethinking the doctor-patient...
 
Kuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care CoordinationKuperman Health Information Exchange & Care Coordination
Kuperman Health Information Exchange & Care Coordination
 
Safran info sage & disruptive innovation
Safran  info sage & disruptive innovationSafran  info sage & disruptive innovation
Safran info sage & disruptive innovation
 
[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis final[Hongsermeier] clinical decision support services amdis final
[Hongsermeier] clinical decision support services amdis final
 
[Teich] amdis
[Teich] amdis[Teich] amdis
[Teich] amdis
 
Hamann big institution to community care
Hamann big institution to community careHamann big institution to community care
Hamann big institution to community care
 
Hongsermeier app store for health
Hongsermeier  app store for healthHongsermeier  app store for health
Hongsermeier app store for health
 
Mandl app store for health
Mandl  app store for healthMandl  app store for health
Mandl app store for health
 
Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...Kibbe expect direct health information exchange in the context of state 2 mea...
Kibbe expect direct health information exchange in the context of state 2 mea...
 
Crotty engaging patients in new ways from open notes to social media
Crotty  engaging patients in new ways from open notes to social mediaCrotty  engaging patients in new ways from open notes to social media
Crotty engaging patients in new ways from open notes to social media
 

Engaging patients through evidence based medicine

  • 1. Engaging Patients Through Evidence-Based Medicine Margaret Holmes-Rovner, PhD MSU College of Human Medicine CMIO Conference, Chicago, Oct 3-4
  • 2. What works? What doesn’t?  Engagement in decision making – Encouraging decision making just before the encounter: question asking and coaching? – Patient access to electronic medical records? – Shared decision making with decision aids? – Patient centered interviewing?  Engagement in chronic disease self- management Kinnersley BMJ 2008; Delbanco Ann Intern Med 2012; Stacy Cochrane 2011; Dwamena Cochrane forthcoming
  • 3. What is Shared Decision Making?  Ensuring patient involvement in decisions – Provide evidence about the condition, options, long term and short term outcomes (Decision Aids help) – Clarify patients‟ values for the outcomes that matter to them (Engage with evidence) – Guide patients so the clinical choice matches their informed values. – Meaningful dialog rather than uni-directional disclosure (provider led, patient engaged) O’Connor et al, Health Affairs, 2007
  • 4. Road to Berwick’s triple aim  Enhance the patient‟s experience (satisfaction increases)  Improve the health of the population through patient engagement (adherence with negotiated plans)  Decrease costs generated by over-use of tests and procedures Stacy D, Cochrane, 2011 Arterburn DE, Health Affairs, 2012
  • 5. Roots in Decision Analysis OpDeath UDead pOpDeath SURGERY NoSurv3 UDead pNoSurv3 Survive SymL1 USymL1 # pSymL1 Surv3 SymL2 USymL2 CABG Medical or Surgical Rx # pSymL2 SymL3 USymL3 # MNoSurv3 UDead pMNoSurv3 MEDICAL MS ymL1 USymL1 pMSymL1 MS urv3 MS ymL2 USymL2 # pMSymL2 MS ymL3 USymL3 #
  • 6. Preference-sensitive decisions?  No one right answer for everyone  Requires time for real informing/deciding  Examples: -Lumpectomy vs mastectomy for early stage breast CA; -Active surveillance vs surgery vs radiation for early stage prostate cancer CA; -Stable CAD (today‟s example)  “Sensitive” here means responsive to patients‟ goals for outcomes AND concerns about side effects.
  • 8.
  • 9.
  • 10. Choosing Wisely?  Toss-ups: marginal added benefit to more aggressive therapies  Therapeutic Misconception is widespread – Patients frequently think surgery means they can skip medical therapy, chronic disease self- management  Patients may choose options providers are not happy about, to date, most often no treatment Smith, BMJ, 2010
  • 11. PCI Example PCI + Meds vs Meds alone in stable CAD  No diff in risk of death or MI  Function/quality of life improved in first 2 yrs. where chest pain not controlled by meds  PCI should be an adjunct to meds in stable CAD  Decreasing PCIs when not appropriate would: – Improve the quality of care for many patients – substantial healthcare savings Boden, COURAGE trial, NEJM, 2007; Trikalinos, Lancet, 2009.
  • 12. PCI Rates by Medicare Hosp. Referral Regions, 2005
  • 13. BCBSM PCI Utilization, 2008, by HRR
  • 14. Where in the diagnostic therapeutic cascade?  Cardiology pre-cath? – Most pressing, proximal to decision – Data suggest patients don‟t change their expectation of preventing heart attacks. – Even “enhanced informed consent” via video in a recent unpublished study doesn‟t change expectations or utilization  Stress test?  Primary care counseling in stable CAD patients for “anticipatory SDM” 14
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20. Intervention is Not just a DA  Initiated in primary care when a stress test is ordered  Cardiology changed their results report to: 1. Normal 2. Abnormal with no high risk features 3. Abnormal with high risk features  # 1,2 go back to primary care for decision  “After visit summary sheet” in primary care  Care manager may do chronic disease self- management in cardiology or in primary care
  • 21. Good Decision Aids exist?  Science is strong – IPDAS update of background – Quality ratings of DAs: www.IPDAS.ohri.ca  Public domain is growing (though limited)  Private companies produce sets of DAs  Recent Mass legislation will strengthen the public domain
  • 22. What’s missing? Leadership  Make it easy: DAs in the hands of providers and patients  Make it delegatable by providers? (No) – Providers need brief training  Improve care coordination? (Yes) – Primary care – Specialist – Providers - Care managers Holmes-Rovner, PEC, 2010
  • 23. References  Arterburn D, et al. Introducing decision aids at Group Health linked to sharply lower hip and knee surgery rates and costs. Health Aff. 2012;31:9,2094-2104.  Boden, et al, COURAGE trial, NEJM. 2007; 2007 Apr 12;356(15):1503  Delbanco et al, Inviting patients to read their doctors‟ notes, Ann Intern Med, 157: 461-470.  Holmes-Rovner M, et al, Shared Decision Making Guidance Reminders In Practice Pat Ed & Coun, 2011 Nov;85(2):219-24.  Kinnersley P, Interventions before consultations to help patients address their information needs by encouraging question asking. BMJ. 2008 Jul 16;337:a485.
  • 24.  O'Connor AM, et al. Toward the „tipping point‟: decision aids and informed patient choice, Health Affairs, 2007 May-Jun;26(3):716- 25.  Smith SK, et al, A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. BMJ, 2010;341.  Stacey D, et al, Dec Aids for people faciing health treatment or screening decisions. Cochrane Database System Reviews 2011, Issue 10.  Trikalinos, PCI for non-acute CAD: quantitat 20-year synopsis and network meta-analysis. Lancet 2009. 2010;341.
  • 25. How to do it? :  Initiate conversation around shared decision-making – Set the stage for the visit – Set an agenda for the visit – Get the patient‟s story  Relate to the patient by – Eliciting emotions – Expressing empathy  Educate the patient about his/her unique situation with disease-specific information (Expanded in SDM.)  Help patient to commit to engaging in the care of his/her stable CAD  Negotiate an action plan (long-term and short-term) with the patient (SDM: 2-way discussion of options, patient goals, how best to accomplish them)  Referral and documentation